RNA 기반 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global RNA based therapeutics market size is expected to reach USD 48.08 Billion in 2034 from USD 19.12 Billion in 2025, growing at a CAGR of 10.79% during 2026-2034.This market is expanding as advances in molecular biology and biotechnology create new opportunities for treatments based on ribonucleic acid. RNA-based therapeutics include approaches such as messenger RNA therapies, small interfering RNA, antisense oligonucleotides, and other RNA-modulating technologies. These treatments can influence protein production or gene expression, offering potential applications in genetic disorders, infectious diseases, cancer, and other medical conditions. Progress in RNA delivery systems and chemical modifications is helping researchers address earlier development challenges. Growing interest in precision medicine is further encouraging pharmaceutical companies to explore RNA-based approaches for targeted therapeutic applications.

Market growth is supported by increasing investment in biotechnology research, advances in lipid nanoparticle delivery, and improved understanding of RNA biology. Pharmaceutical companies are developing candidates designed to address diseases that have historically been difficult to treat using conventional medicines. Research collaborations, licensing agreements, and strategic partnerships are helping companies access specialized technologies and accelerate development programs. Regulatory experience gained from approved RNA-based products is also contributing to the evolution of manufacturing and clinical development practices. In addition, advances in sequencing, computational biology, and molecular design are helping researchers identify new therapeutic targets.

The future prospects of this market depend on improvements in delivery efficiency, treatment durability, manufacturing scalability, and clinical outcomes. Researchers are investigating new approaches for delivering RNA to specific tissues, potentially expanding applications beyond established therapeutic areas. Personalized treatments and combination therapies may create additional opportunities, particularly in oncology and rare diseases. Continued investment in biotechnology infrastructure could support the development of more advanced products. However, challenges involving immune responses, off-target effects, production costs, storage requirements, and long-term safety will remain important. Progress in these areas will help determine how widely RNA-based therapeutics can be adopted in routine medical care.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• RNA Interference (RNAi)
• RNA Antisense

By Application

• Genetic Disorders
• Autoimmune Disorders

By End User

• Research Institutes
• Hospitals & Clinics

COMPANIES PROFILED

• Moderna, BioNTech, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Arcturus Therapeutics, Sarepta Therapeutics, Dicerna Pharmaceuticals, Wave Life Sciences, Avidity Biosciences, Intellia Therapeutics, Regeneron Pharmaceuticals, Pfizer, Sanofi, AstraZeneca, Beam Therapeutics, ProQR Therapeutics, Capstan Therapeutics, ReNAgade Therapeutics

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RNA BASED THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. RNA Interference (RNAi) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. RNA Antisense Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RNA BASED THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Genetic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Autoimmune Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RNA BASED THERAPEUTICS MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RNA BASED THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Application
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Application
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Application
  • 7.4.3 By End User
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Application
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Application
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL RNA BASED THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Moderna
  • 9.2.2 BioNTech
  • 9.2.3 Alnylam Pharmaceuticals
  • 9.2.4 Ionis Pharmaceuticals
  • 9.2.5 Arrowhead Pharmaceuticals
  • 9.2.6 Silence Therapeutics
  • 9.2.7 Arcturus Therapeutics
  • 9.2.8 Sarepta Therapeutics
  • 9.2.9 Dicerna Pharmaceuticals
  • 9.2.10 Wave Life Sciences
  • 9.2.11 Avidity Biosciences
  • 9.2.12 Intellia Therapeutics
  • 9.2.13 Regeneron Pharmaceuticals
  • 9.2.14 Pfizer
  • 9.2.15 Sanofi
  • 9.2.16 AstraZeneca
  • 9.2.17 Beam Therapeutics
  • 9.2.18 ProQR Therapeutics
  • 9.2.19 Capstan Therapeutics
  • 9.2.20 ReNAgade Therapeutics